← Leaderboards
James Cardelli
Louisiana State Univ Hsc Shreveport
$5,208,619
Attributed
$5,363,328
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,363,328 · 7
By mechanism
R42$2,747,975 · 1
R01$1,120,539 · 2
R43$786,646 · 2
R21$398,750 · 1
R41$309,418 · 1
Top collaborators
- Gregory Paul Downey1 shared
Most similar at Louisiana State Univ Hsc Shreveport
Same institution · by research overlap
- Natalie R Lenard$120,795
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposDoseClinical TrialsIn VivoPathologyOralMouse ModelEvaluationS DiseasePharmaceutical PreparationsSafetyBrainNeuroinflammationAffectBehavioralAmyloidPathologicPhase I Clinical TrialsPositioning AttributeAnimal ModelBiotechnologyHuman DiseaseEfficacy StudyLegal Patent
Grant awards (15)
Repurposing Pyrvinium as an Inhalation Therapy for Idiopathic Pulmonary Fibrosis$309,418
R41 · FY2025 · HL · contact PI
Evaluation of a dual PPAR agonist for treatment of Alzheimer's disease$805,761
R42 · FY2023 · AG · contact PI
Evaluation of a dual PPAR agonist for treatment of Alzheimer's disease$249,774
R42 · FY2023 · AG · contact PI
Evaluation of a dual PPAR agonist for treatment of Alzheimer's disease$1,692,440
R42 · FY2022 · AG · contact PI
Evaluation of a selective PPAR-gamma agonist for treatment of Alzheimerâs Disease$103,008
R43 · FY2020 · AG · contact PI
Evaluation of a selective PPAR-gamma agonist for treatment of Alzheimerâs Disease$346,991
R43 · FY2019 · AG · contact PI
Evaluation of oral oleocanthal to prevent and/or treat Alzheimerâs disease and related dementias$67,013
R43 · FY2019 · AG · contact PI
Evaluation of oral oleocanthal to prevent and/or treat Alzheimerâs disease and related dementias$269,634
R43 · FY2018 · AG · contact PI
Role of IFN-gamma Induced Macrophage GTPases in Brucella Killing$108,750
R21 · FY2007 · AI · contact PI
IFN-gamma Induced Macrophage GTPases in Brucella Killing$290,000
R21 · FY2006 · AI · contact PI
HGF Regulated Vesicle Trafficking and Tumor Invasion$247,788
R01 · FY2006 · CA · contact PI
HGF Regulated Vesicle Trafficking and Tumor Invasion$253,750
R01 · FY2005 · CA
HGF Regulated Vesicle Trafficking and Tumor Invasion$253,750
R01 · FY2004 · CA
REGULATION OF PHAGOCYTOSIS$185,261
R01 · FY2001 · DK
REGULATION OF PHAGOCYTOSIS$179,990
R01 · FY2000 · DK